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the median time to the ﬁrst MMF claim of the MMF group. A
multivariate logistic regression and a Wilcoxon test were
employed to assess risk of GI medication use and total medical
costs 1 year before and after occurrence of GI medication claim,
respectively. RESULTS: MMF was received by 173 (74%)
patients. GI medication use occurred in 139 (80%) of the
patients in the MMF group and in 29 (48%) of the patients in
the non-MMF group. Patients who received MMF were associ-
ated with a statistically signiﬁcant increase in risk of GI med-
ication use compared to patients who did not receive MMF (OR
= 7.65, p < 0.0001). Patients using GI medications generated sig-
niﬁcantly greater costs compared to patients not using GI med-
ications ($69,328 vs $48,301, p < 0.0001). CONCLUSIONS:
Heart transplant recipients who receive MMF had 7.7 times
greater risk of using GI medications compared to those who did
not receive MMF, which leads to increased costs.
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OBJECTIVE: To assess the economic consequences of changing
the prescription pattern of proton pump inhibitors (PPI) in
Sweden by use of a budget impact model (BIM). METHODS:
Data from published sources provided information about treat-
ment effects of different PPIs and productivity losses due to
upper gastrointestinal symptoms (GIS). Sale statistics at the
county council level and ofﬁcial Swedish price lists were used to
estimate drug costs. Data on wages ware taken from Statistics
Sweden and was used to estimate indirect costs. The BIM was
ﬂexible and allowed us to analyse (i) the drug budget impact in
a particular county council of switching between different PPIs
and (ii) the annual per patient drug cost and the indirect cost
from treating patients with different PPIs during a speciﬁc time
period. RESULTS: In the county council of Stockholm (1.9
million inhabitants) the annual PPI drug costs amount to about
€11.5 Million of which 50% and 14% comprise of generic
omeprazole and esomeprazole, respectively. The consequence of
switching from generic omeprazole to esomeprazole for 30% of
the patients would result in increasing the PPI drug costs by
11%. However, as the major part of the annual per patient costs
comprise of indirect costs due to productivity losses and absence
from work, esomeprazole only need to be 1–2 percent units more
effective in reducing GIS per week than generic omeprazole to
compensate for its higher price. CONCLUSION: The results
indicate the importance of including both direct and indirect
costs in BIMs when analyzing changes in drug prescription 
patterns.
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OBJECTIVES: Infection with Helicobacter pylori (HP) is asso-
ciated with several clinical conditions; the two most important
in both numbers and costs are peptic ulcer disease and gastric
cancer. In 1999 these two conditions were responsible for more
than 2000 deaths and €94.9 million of direct medical costs in
The Netherlands. A great step forward would be the develop-
ment of a preventive vaccine. The objective of this study is to
estimate the cost-effectiveness of a potential HP vaccine for The
Netherlands. METHODS: We designed a probabilistic Markov
model to fully incorporate the uncertainty associated with the
different transition probabilities. The model followed a birth
cohort during a period of 85 years. Transition probabilities for
the current situation without vaccination were based on Dutch
data. In presence of vaccination these probabilities were adjusted
using the attributive risks and vaccine efﬁcacy. Vaccine efﬁcacy
was assumed at 80% (range: 50–100). The perspective of the
analysis was that of the health care sector; only Dutch direct
medical costs were taken into account. For cost per dose we per-
formed different scenario analyses (base case: €50). For each 
scenario we conducted 10.000 Monte Carlo simulations. Cost-
effectiveness is expressed as net costs per life year gained (LYG)
where costs and effects were discounted according to the current
Dutch guidelines for pharmacoeconomic research (costs: 4%,
effects: 1.5%). RESULTS: For the base case scenario the median
cost-effectiveness ratio is estimated €2700 per LYG. For all sce-
narios investigated cost-effectiveness is estimated below the
informal Dutch threshold of €20,000 per LYG with a probabil-
ity of more than 0.95. CONCLUSIONS: According to our
model, for the greater part based on Dutch data, a potential new
developed HP vaccine could be considered cost-effective as the
cost-effectiveness is estimated below the informal Dutch thresh-
old used by decision makers.
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OBJECTIVES: A pentavalent rotavirus vaccine to prevent
rotavirus gastroenteritis (RVGE) in children will soon become
available. The objective of the study reported here was to assess
the health outcomes and the economic impact in the UK of a RV
vaccination programme vs no programme. METHODS: A birth
cohort was followed up to age 5 using a cohort model. Epi-
demiological parameters were taken from the REVEAL study (a
prospective epidemiological study conducted in the UK, 2004–
2005) and from literature. Costs were assessed from NHS and
societal perspectives by combining health care resource utiliza-
tion collected in REVEAL study and unit costs from ofﬁcial
sources. ITT effectiveness of the vaccine was taken from a large
worldwide clinical trial (70,000 children). Health outcomes
included home care cases, telephone consultations, GP/Acci-
dent&Emergency department visits, hospitalisations and noso-
comial infections. A sensitivity analysis was performed varying
the cost of the RV vaccine course between £80 and £100.
RESULTS: The model estimates that the introduction of a RV
vaccination programme with the pentavalent RV vaccine (90%
coverage rate) would reduce the RVGE burden by 75% in the
UK: 102,290 home care cases, 25,570 telephone consultations,
83,220 GP visits, 5660 Accident&Emergency department visits,
12,220 hospitalisations and 5040 nosocomial infections could be
avoided. The RVGE cost was estimated at £29m and £69m from
NHS and societal perspectives respectively. The introduction of
a RV vaccination programme would reduce the RVGE cost by
about 75% in both perspectives. For a vaccine course ranging
from £80 to £100, the RV vaccination programme is associated
with an incremental cost-effectiveness ratio that varies from
